新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 诺华 » 2014年全球制药巨头药物转化效率TOP10

2014年全球制药巨头药物转化效率TOP10

来源:生物谷 2015-03-18 11:22

一直以来,外界都是简单的通过公司的营业额、新药数目等来衡量一个生物医药公司的实力。但是,如何能更好的衡量一家生物医药公司的创新性?如果手中有一个待开发的药物分子,那么将它交给哪家公司才能实现这种药物的利益最大化?

IDEA公司每年发布的生产创新指数(PII)或许能告诉你答案。这一榜单已经发布了五年,在生物医药产业也引起了广泛的重视。随着过去一年生物医药产业风云变幻,在这份榜单上的十大"武林高手"排名也有着不小的变化。

强生连续三年蝉联榜首

一直以来,强生公司都以药物开发的高效性闻名于生物医药产业。而今年也是强生公司第三年蝉联PII排行榜榜首的位置。公司涉足多种疾病领域,其开发的八种药物的年销售额在过去一年中都超过了两位数增长,达到了14.9%之多。公司开发的Olysio/Sovriad丙肝联合疗法销售额在过去的12个月内达到了20亿美元之多!此外,公司开发的Invokana、Imbruvica 、Zytiga、Invega 、Sustenna 和Rezolsta等新药陆续获批也进一步巩固了其“武林盟主”的地位。

Sovaldi在手,天下我有 吉利德跃居榜眼

最近几年,吉利德公司可谓是风光无限。公司开发的新型丙肝疗法Sovaldi以其惊人的疗效迅速席卷世界医药市场。在短短一年内,这一药物的销售额就达到了惊爆眼珠的100亿美元之多!可谓是Sovaldi在手,天下我有。而在今年的PII指数中,吉利德公司可谓是表现最为抢眼的公司。吉利德由去年的第18位一跃攀升至第2位,其在丙肝治疗领域的成就可谓是功不可没。公司在2014年推出了新型丙肝疗法Harvoni。其开发的白血病新药Zybelig也获得了FDA的突破性疗法认证和上市批准。此外正处于研发阶段的Truvada也有了良好的进展。如此遍地开花的成果,难怪能使去年的第二名--老牌医药巨头--诺华公司甘拜下风。

屈居探花 诺华实力仍不容小觑

虽然今年在PII排行榜上,诺华公司的位置变为第三,但公司对新药的整体研发实力仍十分强大。公司目前的畅销药体系包括Afinitor、Tasigna、Zortress和Gilenya。同时,公司在2014年仍赢得了一系列重要成绩。这其中包括治疗转移性肺癌的Zykadia、治疗牛皮癣药物Cosentyx以及治疗荨麻疹药物Xolair都先后获得FDA批准上市。此外,公司开发的Bexsero获得了FDA的高度重视并被授予突破性药物认证。这些都证明诺华公司仍然是药物转化能力最强的生物医药巨头之一。不过,公司今年在心脏病药物serelaxin以及Tasigna在EMA申请方面的失利被认为是排名下滑的主要原因。

除了上述三家制药公司外,百健艾迪、安进公司以及Celgene公司都纷纷杀入前十,同样表现抢眼。其中,Celgene公司更是从去年的第16位跳至第8位,进步惊人。

the Productive Innovation Index (PII)主要是通过综合考量医药公司的药物销售额、新药获批速度、临床研究损耗率(特别是临床三期研究)等指标来衡量一个生物医药公司开发药物、药物商品化以及药物研发创新能力等方面综合实力的。这一榜单由著名公司IDEA Pharma调查发布,距今已经到了第五个年头。在生物医药产业有着很高的参考价值。(生物谷Bioon.com)

详细英文报道:

Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most effective at developing and commercialising new medicines - bringing innovations to market successfully.

The index can be summarised by the question: if you gave the same molecule to two different companies in early phase, which would make the best of it?

Based on an objective, rolling analysis of each company's performance, between 2009 and 2014, Johnson & Johnson (J&J) has continued to demonstrate its leadership in pharmaceutical product commercialisation, seeing them remain cemented in first place for the third year running, despite a significant shift in companies moving into the top 10.

With eight of its drugs hitting double digit growth across five disease franchises, J&J's worldwide pharmaceutical sales increased by 14.9%, with the star performer being its hepatitis C combination drug Olysio/Sovriad, reaching over $2bn in sales in 12 months. This growth was bolstered further with successful launches for Invokana, Imbruvica and Zytiga, which helped to strengthen its position in the ranking alongside new approvals for Invega Sustenna and Rezolsta.

Notably, the biggest climber - moving up from 18th to take 2nd place - is Gilead Sciences for its standout performance in launching blockbuster drug Sovaldi, pulling in $10bn in revenue in just one year, one of the industry's most successful launches ever. Cited as one to watch in last year's Index, Gilead's undeniable rise was also reinforced by the launch of the first hepatitis C combination pill, Harvoni; the continued return on investment for Stribild; achieving FDA approval and breakthrough designation for Zybelig, and obtaining CDC backing for Truvada. This saw the company knock Novartis down to rank 3rd.

Despite its move, Novartis has remained in the top three in recognition for the continued growth from its core assets Afinitor, Tasigna, Zortress and Gilenya, and contributions from its industry-leading late-stage pipeline. Supporting this were a number of key approvals in 2014 including Zykadia for metastatic lung cancer, Xolair for hives and Cosentyx for psoriasis to name a few. Bexsero also had a good year with a breakthrough designation, winning Prix Galien and FDA approval. What pegged Novartis back was the refusal for serelaxin in heart failure, and pulling the Tasigna EMA application for Philadelphia chromosome positive-CML.

Other companies that made significant moves into the top 10 were Biogen, Amgen and Celgene - the latter was the second biggest climber into the upper echelons, moving from 16th to take 8th place, for successfully expanding its reach from oncology and having an immediate impact in the immunology arena.

Commenting on the index, IDEA Pharma's CEO, Mike Rea said: "PII is the only measure of innovation in the pharma industry that matters - those at the top have made a better job of being a pharma company than those towards the bottom over the past five years. Seeing J&J leading the index once again further secures its stance as a true innovator in the market… after all, innovation is based on what is launched, not what is discovered and is only valuable if it effectively reaches the market and the target patient groups."

The PII looks beyond turnover figures and raw approval rates, or more subjective measures of 'innovation', and assesses companies based on a range of factors including speed to market, attrition rate across phases - in particular phase III, reimbursement rates, regulatory approvals and analyst rankings.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库